Stock Research for CLDX

CLDX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CLDX Stock Chart & Research Data

The CLDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CLDX Due diligence Resources & Stock Charts

The CLDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLDX Detailed Price Forecast - CNN Money CNN View CLDX Detailed Summary - Google Finance
Yahoo View CLDX Detailed Summary - Yahoo! Finance Zacks View CLDX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CLDX Trends & Analysis - Trade-Ideas Barrons View CLDX Major Holders - Barrons
NASDAQ View CLDX Call Transcripts - NASDAQ Seeking View CLDX Breaking News & Analysis - Seeking Alpha
Spotlight View CLDX Annual Report - CompanySpotlight.com OTC Report View CLDX OTC Short Report - OTCShortReport.com
TradeKing View CLDX Fundamentals - TradeKing Charts View CLDX SEC Filings - Bar Chart
WSJ View Historical Prices for CLDX - The WSJ Morningstar View Performance/Total Return for CLDX - Morningstar
MarketWatch View the Analyst Estimates for CLDX - MarketWatch CNBC View the Earnings History for CLDX - CNBC
StockMarketWatch View the CLDX Earnings - StockMarketWatch MacroAxis View CLDX Buy or Sell Recommendations - MacroAxis
Bullish View the CLDX Bullish Patterns - American Bulls Short Pains View CLDX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CLDX Stock Mentions - StockTwits PennyStocks View CLDX Stock Mentions - PennyStockTweets
Twitter View CLDX Stock Mentions - Twitter Invest Hub View CLDX Investment Forum News - Investor Hub
Yahoo View CLDX Stock Mentions - Yahoo! Message Board Seeking Alpha View CLDX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CLDX - SECform4.com Insider Cow View Insider Transactions for CLDX - Insider Cow
CNBC View CLDX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLDX - OTC Markets
Yahoo View Insider Transactions for CLDX - Yahoo! Finance NASDAQ View Institutional Holdings for CLDX - NASDAQ


Stock Charts

FinViz View CLDX Stock Insight & Charts - FinViz.com StockCharts View CLDX Investment Charts - StockCharts.com
BarChart View CLDX Stock Overview & Charts - BarChart Trading View View CLDX User Generated Charts - Trading View


Latest Financial News for CLDX

Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018
Posted on Friday April 20, 2018

Celldex Therapeutics, Inc. (CLDX) today announced promising early data from an investigator-initiated pilot study evaluating the combination of CDX-301 and stereotactic body radiotherapy (SBRT) in patients with advanced non-small cell lung cancer (NSCLC). CDX‑301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells.


Analysis: Positioning to Benefit within Celldex Therapeutics, McDermott International, Briggs & Stratton, Tile Shop Hldgs, Essendant, and Anworth Mortgage Asset — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Friday April 20, 2018

NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...


Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
Posted on Wednesday April 18, 2018

The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.


Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
Posted on Tuesday April 17, 2018

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.


Enter a stock symbol to view the stock details.